Search

Displaying results 2111 - 2120 of 4262 in total
  1. Drug

    Oxcarbazepine

    go.drugbank.com/drugs/DB00776
    ApprovedInvestigational

    Oxcarbazepine is an anti-epileptic medication used in the treatment of partial onset seizures that was first approved for use in the United States in 2000. It is a structural derivative of carbamazepine and exerts a majority of its activ...

  2. Drug

    Crizanlizumab

    go.drugbank.com/drugs/DB15271
    ApprovedInvestigational

    It was developed by Novartis and was granted FDA approval on November 15, 2019.

  3. Drug

    Enoxacin

    go.drugbank.com/drugs/DB00467
    Approved

    A broad-spectrum 6-fluoronaphthyridinone antibacterial agent (fluoroquinolones) structurally related to nalidixic acid.

  4. Drug

    Phosphocreatine

    go.drugbank.com/drugs/DB13191
    InvestigationalNutraceutical

    Phosphocreatine - or creatine phosphate - is the phosphorylated form of creatine. It is primarily found endogenously in the skeletal muscles of vertebrates where it serves a critical role as a rapidly acting energy buffer for muscle cell...

  5. Drug

    Eugenol

    go.drugbank.com/drugs/DB09086
    ApprovedInvestigational

    Eugenol is a naturally occurring phenolic molecule found in several plants such as cinnamon, clove, and bay leaves.

  6. Drug

    Pheniprazine

    go.drugbank.com/drugs/DB09250
    ApprovedWithdrawn

    Pheniprazine was withdrawn by its manufacturer due to its ability to cause toxicity in the liver and its ability to cause optic neuritis.

  7. Drug

    Norgestimate

    go.drugbank.com/drugs/DB00957
    ApprovedInvestigational

    [A191068] It was developed by Ortho Pharmaceutical Corporation as part of an effort to develop new hormonal contraceptives with reduced adverse effects.

  8. Drug

    Talquetamab

    go.drugbank.com/drugs/DB16678
    ApprovedInvestigational

    It consists of two arms - anti-GPRC5D and anti-CD3 arms - linked by two interchain disulfide bonds, each arm comprising a heavy and light chain. … [L47775] Talquetamab was fully approved by the EMA on August 22, 2023.[L48822] On August 9, 2023, talquetamab was granted FDA accelerated approval.[L47770]

  9. Drug

    Clomifene

    go.drugbank.com/drugs/DB00882
    ApprovedInvestigational

    A triphenyl ethylene stilbene derivative which is an estrogen agonist or antagonist depending on the target tissue.

  10. Drug

    Mobocertinib

    go.drugbank.com/drugs/DB16390
    ApprovedInvestigationalWithdrawn

    It is used specifically in the treatment of non-small cell lung cancer (NSCLC) caused by exon 20 insertion mutations in the _EGFR_ gene,[L38368] which are typically associated with a poorer prognosis ( … [L38319] Mobocertinib, under the brand name Exkivity (Takeda Pharmaceuticals Inc.), was granted accelerated approval by the FDA in September 2021 for the treatment of locally advanced or metastatic